Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents

Autor: Maldonado-Rojas, Andrea del Carmen, Zuarth-Vázquez, Julia María, Uribe, Misael, Barbero-Becerra, Varenka J

Publikováno v: In Annals of Hepatology March-April 2024 29(2)

Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents.

Autor: del Carmen Maldonado-Rojas, Andrea, Zuarth-Vázquez, Julia María, Uribe, Misael, Barbero-Becerra, Varenka J.

Publikováno v: Annals of Hepatology: Official Journal of the Mexican Association of Hepatology; Mar/Apr2024, Vol. 29 Issue 2, p1-7, 7p

Fibroblast growth factor 21 is associated with increased serum total antioxidant capacity and oxidized lipoproteins in humans with different stages of chronic kidney disease

Autor: López Estrada Angelina, Espinosa Cuevas Ángeles, Gómez Pérez Francisco J, Guillén Pineda Luz Elizabeth, Palacios Báez Lucía, Navarro Flores María Fernanda, Gómez Sámano Miguel Ángel, Rincón Pedrero Rodolfo, Zuarth Vázquez Julia María, Morales García Mariana Guadalupe, Martínez Sánchez Froylan David, López Cervantes Malaquías, Vargas Abonce Valerie Paola, Ramírez González Julia Berenice, Vera Zertuche Juan Mauricio, Baeza Arias Yolanda Victoria, Pacheco Domínguez Reyna Lizette, Correa Rotter Ricardo, Morales Buenrostro Luis E, Vega Vega Olynka, López Carrasco Guadalupe, Fonseca Correa Jorge Ignacio, Alberú Gómez Josefina, Mendoza de la Garza María de los Ángeles, Cuevas Ramos Daniel

Publikováno v: Therapeutic Advances in Endocrinology and Metabolism, Vol 12 (2021)
Therapeutic Advances in Endocrinology and Metabolism

Background and aims: Oxidative stress (OS) induces the production of fibroblast growth factor 21 (FGF21). Previous data have revealed that FGF21 protects cells from OS injury and death, making it a potential therapeutic option for many diseases with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c20818bed1e78aac7da1fd3cd8f57ae9
https://doaj.org/article/ed8f8c30bd604a19a77faa33f4ab00c3

Fibroblast growth factor 21 is associated with increased serum total antioxidant capacity and oxidized lipoproteins in humans with different stages of chronic kidney disease.

Autor: Gómez-Sámano MÁ; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Vargas-Abonce VP; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Martínez-Sánchez FD; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Palacios-Báez L; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Vera-Zertuche JM; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Navarro-Flores MF; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Morales-García MG; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Fonseca-Correa JI; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Zuarth-Vázquez JM; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Vega-Vega O; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Correa-Rotter R; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Rincón-Pedrero R; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Morales-Buenrostro LE; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Alberú-Gómez J; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Ramírez-González JB; Department of Preventive Medicine and Public Health, Universidad Nacional Autónoma de México, Mexico City, Mexico., Pacheco-Domínguez RL; Department of Preventive Medicine and Public Health, Universidad Nacional Autónoma de México, Mexico City, Mexico., López-Cervantes M; Department of Preventive Medicine and Public Health, Universidad Nacional Autónoma de México, Mexico City, Mexico., Mendoza-de-la-Garza MLÁ; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Baeza-Arias YV; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Espinosa-Cuevas Á; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., López-Carrasco G; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., López-Estrada A; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Guillén-Pineda LE; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Gómez-Pérez FJ; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Cuevas-Ramos D; Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Vasco de Quiroga # 15, Sección XVI Tlalpan 14000, Mexico City, Mexico.

Publikováno v: Therapeutic advances in endocrinology and metabolism [Ther Adv Endocrinol Metab] 2021 Mar 29; Vol. 12, pp. 20420188211001160. Date of Electronic Publication: 2021 Mar 29 (Print Publication: 2021).